We create high-quality medicines and make them accessible to people who need them. Global experts with a local presence, we think creatively and act practically. We develop innovative solutions that transform people’s lives, for a healthier world wherever we are.

Messages from the Board


3576.
quotemark graphic

This is an exciting time for Hikma as we embark on our next chapter of growth. As we invest in the future, we maintain our commitment to strong corporate governance, the highest quality standards and to improving the lives of our patients and our communities."

Said Darwazah Executive Chairman
3563.
quotemark graphic

By inspiring and enabling our people to develop a portfolio that meets the future needs of doctors and patients, we are building a business that can deliver sustainable growth over the long term."

Sigurdur Olafsson Chief Executive Officer

Five reasons to invest in Hikma

We have a long track record of creating value for our shareholders. By focusing on our strategic priorities and leveraging our strengths, we can build upon our success.

  

Our business model


Our business model enables us to respond to the many opportunities and challenges we face.

Our strategy


By focusing on our strategy, we will deliver sustainable growth over the long-term.

Our operations

Our Injectables business develops and manufactures generic injectable products. Our products are sold globally and are primarily used in hospitals.

Core revenue ($m)


40% of Group revenue (2017: 40%)



Working with our customers to address critical shortage

Our Generics business develops and manufactures oral and other non-injectable generic products. Our products are sold in the US retail market.

Revenue ($m)


33% of Group revenue (2017: 32%)



Improving patient’s access to ritonavir

Our Branded business develops, manufactures and markets branded generic and in-licensed patented products in MENA. Our products are sold in the retail and hospital markets.

Revenue ($m)


26% of Group revenue (2017: 28%)



Improving access to an important MS treatment